Form D · Biotechnology
Emulate, Inc.
Boston, MA · CIK 0001614538
Offering snapshot reported Sep 7, 2021 · SEC filing
- Reported sold
- $57.5M Offering amount: $57.5M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 23, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 7, 2021 | Initial | $57,499,997 | No comparison | 7 | SEC filing |
| Mar 23, 2020 | Initial | $19,275,000 | No comparison | 9 | SEC filing |
| Aug 16, 2019 | Initial | $27,994,991 | No comparison | 8 | SEC filing |
| Jun 21, 2018 | Initial | $35,999,998 | No comparison | 41 | SEC filing |
| Nov 9, 2017 | Initial | $745,750 | No comparison | 4 | SEC filing |
| Mar 28, 2016 | Initial | $28,750,000 | No comparison | 10 | SEC filing |
| Jul 28, 2014 | Initial | $12,000,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-412499
Source: Form D, filed Sep 7, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James David Coon | Director, Executive |
| David James Coon | Director, Executive |
| James Corbett | Director, Executive |
| Harminder Dhaliwal | Executive |
| Michael Egholm | Director |
| Geraldine Hamilton | Director, Executive |
| Donald Ingber | Director |
| Scott Kantor | Executive |
| Sharon Kedar | Director |
| Sandy Lazzari | Executive |
| Daniel Levner | Director, Executive |
| Martin Madaus | Director |
| Shlomo Melmed | Director |
| Eric Moessinger | Director |
| Monique Noel | Executive |
| Lewis Rowe | Executive |
| Andrew Stevenson | Director |
| Aaron Van Devender | Director |
| Larry Weiss | Executive |
| Gregory D. Williams | Executive |
| Franklin Witney | Director |
| Hansjoerg Wyss | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
27 Drydock Avenue, 5 Th Floor
Boston, MA, 02210
Boston, MA, 02210